Benchmark Co. analyst Bruce Jackson has reiterated their bullish stance on HUMA stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bruce Jackson has given his Buy rating due to a combination of factors that highlight Humacyte’s promising market position and financial performance. The company successfully launched its product, Symvess, in February and has already begun generating revenue, which was unexpected for the first quarter of 2025. This launch has been well-received, with 45 hospitals initiating the process to adopt the product, covering a significant portion of Level 1 trauma centers in the U.S.
Additionally, Humacyte’s financial health appears robust, with strong gross margins of 71.6% and a solid cash position of $62.8 million, excluding restricted cash. The company has also taken strategic steps to extend its cash runway by reducing its workforce and deferring new hires. These factors, combined with a promising pipeline of new products and a supportive economic model for Symvess, underpin Jackson’s confidence in the company’s future growth and market share expansion.
According to TipRanks, Jackson is an analyst with an average return of -20.5% and a 29.00% success rate. Jackson covers the Healthcare sector, focusing on stocks such as Humacyte, Harvard Bioscience, and Genelux Corp..
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target.